Method of treating diseases

1. A method of treating acromegaly in a subject, the method comprising:

a) orally administering to the subject at least one dosage form comprising octreotide, wherein the subject is administered an H2-receptor antagonist or an antacid;

b) monitoring IGF-1 and clinical symptoms or biochemical and symptomatic response of the subject; and

c) if IGF-1 is not normal and clinical symptoms are not controlled or biochemical and symptomatic response is not maintained, then increasing the total dose of oral octreotide administered to the subject;

wherein the dosage form comprises:

a composition comprising a suspension which is an admixture of a hydrophobic medium and a solid form,

wherein the solid form comprises: a therapeutically effective amount of octreotide and a medium chain fatty acid salt, wherein the composition comprises 12% to 18% by weight of the medium chain fatty acid salt.

2. The method of claim 1 , wherein the amount of octreotide in each dosage form is 20 mg.

3. The method of claim 1 , wherein the administering of octreotide occurs at least 1 hour before a meal or at least 2 hours after a meal.

4. The method of claim 1 , wherein the dosage form comprises an oily suspension which is formulated into a capsule.

5. The method of claim 4 , wherein the capsule is enterically coated.

6. The method of claim 1 , wherein the administering of octreotide occurs twice daily.

7. The method of claim 6 , wherein the subject is dosed in the morning and in the evening, comprising a first and second administration.

8. The method of claim 7 , wherein the first administration includes one or two dosage forms and the second administration includes one or two dosage forms.

9. The method of claim 7 , wherein the first administration includes one dosage form and the second administration includes one dosage form.

10. The method of claim 7 , wherein the first administration includes two dosage forms and the second administration includes one dosage form.

11. The method of claim 7 , wherein the first administration includes two dosage forms and the second administration includes two dosage forms.

12. The method of claim 1 , wherein one dosage form is administered twice a day.

13. The method of claim 1 , wherein two dosage forms are administered twice a day.

14. The method of claim 1 , wherein one dosage form is administered once a day and two dosage forms are administered once a day.

15. The method of claim 1 , wherein the total amount of octreotide administered per day to the subject is 40 mg, 60 mg, or 80 mg.

16. The method of claim 1 , wherein the medium chain fatty acid salt is sodium octanoate.

17. The method of claim 1 , wherein the solid form further comprises a matrix forming polymer.

18. The method of claim 17 , wherein the composition comprises 5% to 15% by weight of the matrix forming polymer.

19. The method of claim 17 , wherein the matrix forming polymer is polyvinylpyrrolidone (PVP).

20. The method of claim 19 , wherein the matrix forming polymer is PVP and the medium chain fatty acid salt is sodium octanoate.

21. The method of claim 20 , wherein the composition comprises 12% to 18% by weight of sodium octanoate, 5% to 15% by weight of polyvinylpyrrolidone, 20% to 80% by weight of glyceryl tricaprylate, and 3% to 10% by weight of a surfactant.

22. The method of claim 21 , wherein the surfactant is glyceryl monocaprylate or polyoxyethylene sorbitan monooleate, or a combination thereof.

23. The method of claim 1 , wherein the composition comprises about 65% by weight of glyceryl tricaprylate, about 4% by weight of glyceryl monocaprylate, about 2% by weight of polyoxyethylene sorbitan monooleate, about 15% by weight of sodium octanoate, about 10% by weight of polyvinylpyrrolidone having a molecular weight of about 3000 and about 1% to about 5.5% by weight of octreotide.

24. The method of claim 1 , wherein the dosage form is an enterically coated capsule.

25. The method of claim 1 , wherein the octreotide is octreotide acetate.